Skip to main content

Table 1 Baseline characteristics of included studies

From: Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis

Author

year

Country

Diagnosis

Regimes of anti-lymphoma treatment

Regimes of AT treatment

Follow-up (m)

Median (range)

HCV infection

R use in HCV + patients

AT in HCV + patients

Hazard ratio

yes

no

yes

no

yes

no

Besson [9]

2006

France

DLBCL

47 (0–112)

26

5560

Extrapolated

Chen [10]

2015

China

DLBCL

I-CHT

36 (0.84–96.24)

29

139

29

0

Extrapolated

Chen [11]

2015

China

DLBCL

I-CHT

22

102

15

7

Reported

Dlouhy [12]

2017

Spain

DLBCL

I-CHT

48 (1.2–146.4)

31

290

31

0

Extrapolated

Elbedewy [13]

2020

Egypt

DLBCL

I-CHT

76

277

33

43

34

42

Reported

Ennishi [14]

2010

Japan

DLBCL

I-CHT

DAA

HCV+ 31 (4–42)

HCV− 32 (5–51)

131

422

131

0

7

124

Reported

Hosry [17]

2016

USA

DLBCL

I-CHT

IFN, Rib, DAA

> 6

76

228

76

0

26

40

Extrapolated

Nishikawa [29]

2012

Japan

DLBCL

I-CHT

HCV+ 40.8 (3.6–92.4)                         

HCV− 31.2 (2.4–94.8)

28

220

28

0

0

28

Extrapolated

Park [16]

2008

Korea

DLBCL

I-CHT

37.8

32

371

Extrapolated

Shimono [18]

2019

Japan

ps-DLBCL

I-CHT

HCV + 46.9 (4.0–94.3)

HCV− 36.8 (0.8–133.5)

12

46

10

2-

Extrapolated

Ordinary DLBCL

I-CHT

HCV+ 27.8 (1.9–122.1)

HCV− 35.9 (0.1–90.1)

25

120

Extrapolated

Arcaini [30]

2007

Italy

Non-gastric MALToma

CHT, RT, surgery

60

112

Extrapolated

Arcaini [31]

2006

Italy

SMZL

splenectomy, IFN

37.2

49

206

Hosry [32]

2020

USA

FL

I-CHT, RT

IFN, Rib, DAA

19

57

13

6

Nesterova [33]

2020

Russia

FL

I-CHT

DAA

11

105

11

0

11

0

De Vita [34]

1997

Italy

B-NHL

35

122

Luppi [35]

1998

Italy

B-NHL

IFN, CHT

72

35

122

0

35

Extrapolated

La Mura [36]

2008

Italy

NHL

CHT

IFN, Rib

69

274

0

69

25

44

Extrapolated

Strianese [37]

2010

Italy

OA lymphoma

I-CHT, RT

Mean 75 (12–185)

23

106

Extrapolated

Tajima [38]

2017

Japan

NHL

66

1316

Vallisa [39]

1999

Italy

NHL

CHT, surgery

30 (1–68)

65

110

0

65

Arcaini [19]

2014

Italy

indolent NHL

surgery, I-CHT, RT

IFN, Rib

42 (6–204)

704

0

126

578

134

570

Reported

Merli [15]

2014

Italy

DLBCL

surgery, I-CHT, RT

IFN, Rib

24 (12–168)

535

0

255

280

23

512

Reported

Michot [20]

2015

France

NHL

surgery, I-CHT, RT

IFN, Rib

31 (19–71)

116

0

70

46

Reported

Persico [40]

2018

Italy

DLBCL

I-CHT

DAA

12

121

0

70

51

20

101

Extrapolated

Rattotti [21]

2019

Italy

Indolent NHL

I-CHT, antibiotics

IFN, Rib

36 (1‐84)

138

0

36

102

Extrapolated

Aggressive NHL

112

0

17

95

Salah-Eldin [41]

2014

Egypt

DLBCL

I-CHT

41 (38.6–43.4)

280

0

200

80

0

0

Reported

Zaky [22]

2014

Egypt

DLBCL

I-CHT

36 (5–42)

137

0

68

69

Extrapolated

  1. Abbreviation:  AT antiviral treatment, CHT chemotherapy, DAA direct-acting antiviral, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, I-CHT immunochemotherapy, IFN interferon, MALToma mucosa-associated lymphoid tissue lymphoma, NHL non-Hodgkin’s lymphoma, OA ocular adnexal, ps-DLBCL primary splenic diffuse large B-cell lymphoma, SMZL splenic marginal zone lymphoma, R rituximab, RT radiotherapy, Rib Ribavirin